A new pre-clinical study published in the Journal of Neuroscience shows that a new class of medication is showing promising potential for the treatment and management of Alzheimer’s disease in addition to Parkinson’s, Multiple Sclerosis, and brain injury.
A new class of medication, being developed by Northwestern University Feinberg School of Medicine, is different from medications being tested to prevent beta amyloid plaques in the brain. While beta amyloid plaques are indicators or Alzheimer’s, they have not yet been proved to cause the disease
The pre-clinical study published in the Journal of Neuroscience reports that when the new medication is administered to a mouse genetically engineered to develop Alzheimer’s, it promptly prevents development of full-blown Alzheimer’s
A recent press statement demonstrates that Northwestern University Feinberg School of Medicine has already patented the mediation and has licensed commercial development and has just passed a first phase clinical trial which has tested safely in humans.
As time goes on, more researchers are coming around to the theory that inflammation plays a massive role in the damage that characterizes Alzheimer's, Multiple Sclerosis, Parkinson’s, and also in traumatic brain injury including strokes. This new type of medication, known as MW151 or MW189, targets this inflammation that is so commonly associated with these chronic neurological diseases.
MW151 works as a selective suppressor of brain inflammation and overproduction of inflammatory molecules from glial cells. Because of this, results show that using the medication before Alzheimer’s is apparent may prove to be an exciting therapeutic option. Results show that the medication was both effective before and after symptoms were observable, but that it was most effective when used preventatively.